MedDataX Logo

PREdiction of succeSSful weanING From Continuous Renal Replacement Theraphy: the Possible Role of Delta C-cistatin

NCT ID: NCT06714214

Last Updated: 2024-12-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

152 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-10-01

Study Completion Date

2026-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this observational study is to know if, in patients with acute kidney injury, naive for renal injurie, admitted to different ICUs, the change in plasma concentration of c-cistatin, between initiation and discontinuation of CRRT, is a predictive finding to optimize the withdrawal time of renal support

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Kidney Injury

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

C cistatin acute kidney injury CRRT weaning

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age ≥ 18 years;
* diagnosis of acute kidney injury (defined according to KDIGO 2012 criteria)
* need for support with CRRT according to the indications of the nephrologist consultants and Clinical Practice
* Obtaining informed consent

Exclusion Criteria

* CRRT already ongoing (in another department not participating in the study) at the time of transfer/admission to intensive care;
* need for RRT (any type and modality) in the 14 days prior to enrolment;
* diagnosis of AKD/CKD/ESRF on admission;
* Discontinuation of CRRT under conditions that do not comply with the criteria established by the study;
* Need for CRRT not associated with AKI condition (e.g. elimination of toxicants);
* pregnant women;
* presence of known thyreopathy
* Continuous use of corticosteroids
* patient with known neoplastic disease.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

IRCCS Azienda Ospedaliero-Universitaria di Bologna

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Francesco Marino, MD

Role: PRINCIPAL_INVESTIGATOR

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

IRCCS Azienda Ospedaliero-Universitaria di Bologna - Anestesia e Terapia Intensiva nelle emergenze locali, regionali e nazionale e nella chirurgia addominale maggiore

Bologna, , Italy

Site Status RECRUITING

IRCCS Azienda Ospedaliero-Universitaria di Bologna -Anestesiologia e terapia intensiva polivalente

Bologna, , Italy

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Italy

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Francesco Marino, MD

Role: CONTACT

Phone: 3293842166

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Francesco Marino, MD

Role: primary

Tommaso Tonetti, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PRESSING

Identifier Type: -

Identifier Source: org_study_id